Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2021 financial results after the market close on Monday, February 14, 2022. The Company will host a conference call the following morning, Tuesday, February 15, 2022, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 9164466.
To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com . The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.
A recording of the call will be available until Tuesday, February 22, 2022. To hear this recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 9164466.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,400 people across 40 countries as of September 30, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005958/en/
Investor Contact:
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
Media Contact:
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com